Risk factors

Globa Terra Acquisition Corp is a newly public blank check company searching for an initial business combination.

The supplied section is largely financial and governance disclosure rather than conventional risk-factor narratives.

Clinical losses reached $48.3M in 2025, driven by the global Phase 3 trial for IKT-001 in PAH. Regulatory and data-transfer restrictions under new DOJ rules and U.S. government march-in rights threaten operations. Co-owned patents with Sphaera Pharma and reliance on AI tools increase legal and compliance exposure.

Net losses narrowed to $50.2 million in 2025 from $60.7 million in 2024, with accumulated deficit reaching $400.8 million. Research and development expenses increased to $15.9 million as clinical trials for GraftAssureDx began. FDA enforcement discretion rules for LDTs experienced regulatory shifts and legal challenges.

Indigo Acquisition Corp. has no operating history, depends on completing a business combination by April 2, 2027, and faces severe going concern doubts.

Company is now concentrated on its IoT business after selling its physical security operations. Manufacturing depends entirely on a sole facility in Thailand, exposing operations to tariffs and supply disruptions.

A new 1% Inflation Reduction Act excise tax may reduce security value and hinder the initial business combination.

Clinical-stage biopharmaceutical company focused on psychiatric and neurological conditions with no history of commercializing products.

Lands' End faces significant new risks related to the Pending WHP Transaction, including a $50 million annual royalty obligation.

California-heavy brokerage depends on MLS access, customer acquisition, reliable technology, and favorable residential transaction conditions.

Interlink Electronics removed specific risks related to its Series B Preferred Stock and Series A Convertible Preferred Stock, while updating manufacturing locations and insider ownership figures.

Microbot transitioned from a research-stage company to commercializing its sole product, the LIBERTY Endovascular Robotic Surgical System.